Drug intelligence / Profile preview

Xibisan

Development stage: Preclinical
Lead developer: Chongqing Nanchuan District Hospital of Traditional Chinese Medicine
Administration: Topical

Overview

**Xibisan** is a traditional Chinese medicine herbal preparation administered by external application for knee osteoarthritis characterized in traditional Chinese medicine as cold-damp obstruction. It is being evaluated in a randomized controlled study sponsored by Chongqing Nanchuan District Hospital of Traditional Chinese Medicine. The public registry record does not disclose its constituent herbs, molecular targets, or a pharmacologically defined mechanism of action. ([chictr.org.cn](https://www.chictr.org.cn/showproj.html?proj=196139))

Other names: 膝痹散

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)CASP3 (Caspase-3)RELA (Nuclear Factor Kappa B Subunit p65)

Beyond the preview

Go deeper on Xibisan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xibisan.

Explore the full profile